{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:44:07Z","timestamp":1780631047511,"version":"3.54.1"},"reference-count":39,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Hydrochlorothiazide has been associated with increased cutaneous squamous cell carcinoma risk. Meanwhile, its association with basal cell carcinoma (BCC) risk is controversial. The association between commonly prescribed antihypertensive medications and BCC risk in the Swedish population was investigated. All cases with a histopathologically verified BCC in Sweden during 2007\u20132017 and 2 matched controls per case were included in this nationwide, registry-based, case-control study. Information on prescribed anti-hypertensive drugs, comorbidities, co-medications, and socioeconomic factors was retrieved from nationwide registries. The odds of being treated with any of the chosen treatments in relation to BCC diagnosis were estimated. In total, 133,539 cases and 257,849 controls were studied. Thiazide-containing combination treatments (OR 1.09), angiotensin II receptor blockers (OR 1.09), calcium channel blockers (OR 1.09), and beta-blockers (OR 1.07) were associated with an increased BCC risk. Use of single-agent thiazide treat-ment did not affect BCC risk. In conclusion, statistically significant associations were found between several commonly prescribed antihypertensives and an increased BCC risk. Thiazide treatment affected BCC risk only when given as combination treatment, indicating that relevant adjunctive substances should be studied further in relation to BCC risk. Presently, it is suggested that prevention efforts focus on UV protection rather than altering antihypertensive treatments.<\/jats:p>","DOI":"10.2340\/actadv.v105.42749","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:06:26Z","timestamp":1758618386000},"page":"adv42749","source":"Crossref","is-referenced-by-count":3,"title":["Antihypertensive Medication as a Risk Factor For Basal Cell Carcinoma: A Nationwide Registry-based Case-control Study"],"prefix":"10.2340","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1608-4099","authenticated-orcid":false,"given":"Johan","family":"Kappelin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingela","family":"Ahnlide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6797-1301","authenticated-orcid":false,"given":"Gustav B.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5876-0190","authenticated-orcid":false,"given":"\u00c5sa","family":"Ingvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7363-0455","authenticated-orcid":false,"given":"Kari","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"127338","doi-asserted-by":"crossref","unstructured":"Verkouteren JA, Ramdas KH, Wakkee M, Nijsten T. Epidemiology of basal cell carcinoma: scholarly review. Br J Dermatol 2017; 177: 359\u2013372.","DOI":"10.1111\/bjd.15321"},{"key":"127339","doi-asserted-by":"crossref","unstructured":"Kappelin J, Green AC, Ingvar A, Ahnlide I, Nielsen K. Incidence and trends of basal cell carcinoma in Sweden: a population-based registry study. Br J Dermatol 2022; 186: 963\u2013969.","DOI":"10.1111\/bjd.20964"},{"key":"127340","unstructured":"Statistik om l\u00e4kemedel 2021. 2022. [Accessed: 2023 October 25]. Available from: https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/statistik\/2022-4-7842.pdf."},{"key":"127341","unstructured":"Statistik om l\u00e4kemedel 2023. 2024. [Accessed: 2024 April 18]. Available from: https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/statistik\/2024-4-9026.pdf."},{"key":"127342","doi-asserted-by":"crossref","unstructured":"Tang H, Fu S, Zhai S, Song Y, Asgari MM, Han J. Use of antihypertensive drugs and risk of keratinocyte carcinoma: a meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2018; 27: 279\u2013288.","DOI":"10.1002\/pds.4384"},{"key":"127343","doi-asserted-by":"crossref","unstructured":"Shin D, Lee ES, Kim J, Guerra L, Naik D, Prida X. Association between the use of thiazide diuretics and the risk of skin cancers: a meta-analysis of observational studies. J Clin Med Res 2019; 11: 247\u2013255.","DOI":"10.14740\/jocmr3744"},{"key":"127344","doi-asserted-by":"crossref","unstructured":"Pedersen SA, Gaist D, Schmidt SAJ, Holmich LR, Friis S, Pottegard A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. J Am Acad Dermatol 2018; 78: 673\u2013681 e679.","DOI":"10.1016\/j.jaad.2017.11.042"},{"key":"127345","doi-asserted-by":"crossref","unstructured":"Adalsteinsson JA, Muzumdar S, Waldman R, Hu C, Wu R, Ratner D, et al. Association between hydrochlorothiazide and the risk of in situ and invasive squamous cell skin carcinoma and basal cell carcinoma: a population-based case-control study. J Am Acad Dermatol 2021; 84: 669\u2013675.","DOI":"10.1016\/j.jaad.2020.08.025"},{"key":"127346","doi-asserted-by":"crossref","unstructured":"Morales DR, Pacurariu A, Slattery J, Kurz X. Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: a series of population-based nested case-control studies. Br J Clin Pharmacol 2020; 86: 1336\u20131345.","DOI":"10.1111\/bcp.14245"},{"key":"127347","doi-asserted-by":"crossref","unstructured":"Le\u00f3n-Mu\u00f1oz LM, Duarte-Salles T, Llorente A, D\u00edaz Y, Puente D, Potteg\u00e5rd A, et al. Use of hydrochlorothiazide and risk of skin cancer in a large nested case-control study in Spain. Pharmacoepidemiol Drug Saf 2021; 30: 1269\u20131278.","DOI":"10.1002\/pds.5295"},{"key":"127348","doi-asserted-by":"crossref","unstructured":"Kaae J, Boyd HA, Hansen AV, Wulf HC, Wohlfahrt J, Melbye M. Photosensitizing medication use and risk of skin cancer. Cancer Epidemiol Biomarkers Prev 2010; 19: 2942\u20132949.","DOI":"10.1158\/1055-9965.EPI-10-0652"},{"key":"127349","doi-asserted-by":"crossref","unstructured":"Schneider R, Reinau D, Stoffel S, Jick SS, Meier CR, Spoendlin J. Risk of skin cancer in new users of thiazides and thiazide-like diuretics: a cohort study using an active comparator group. Br J Dermatol 2021; 185: 343\u2013352.","DOI":"10.1111\/bjd.19880"},{"key":"127350","doi-asserted-by":"crossref","unstructured":"de Vries E, Trakatelli M, Kalabalikis D, Ferrandiz L, Ruiz-de-Casas A, Moreno-Ramirez D, et al. Known and potential new risk factors for skin cancer in European populations: a multicentre case-control study. Br J Dermatol 2012; 167: 1\u201313.","DOI":"10.1111\/j.1365-2133.2012.11081.x"},{"key":"127351","doi-asserted-by":"crossref","unstructured":"Jensen AO, Thomsen HF, Engebjerg MC, Olesen AB, Sorensen HT, Karagas MR. Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study. Br J Cancer 2008; 99: 1522\u20131528.","DOI":"10.1038\/sj.bjc.6604686"},{"key":"127352","doi-asserted-by":"crossref","unstructured":"Schmidt SA, Schmidt M, Mehnert F, Lemeshow S, Sorensen HT. Use of antihypertensive drugs and risk of skin cancer. J Eur Acad Dermaol Venereol 2015; 29: 1545\u20131554.","DOI":"10.1111\/jdv.12921"},{"key":"127353","doi-asserted-by":"crossref","unstructured":"Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA, Trial V. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst 2008; 100: 1223\u20131232.","DOI":"10.1093\/jnci\/djn262"},{"key":"127354","doi-asserted-by":"crossref","unstructured":"Moscarelli L, Zanazzi M, Mancini G, Rossi E, Caroti L, Rosso G, et al. Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients. Clin Nephrol 2010; 73: 439\u2013445.","DOI":"10.5414\/CNP73439"},{"key":"127355","unstructured":"Basal Cell Carcinoma in Sweden 2004\u20132008. 2009. [Accessed: 2023 May 23]. Available from: https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/statistik\/2009-12-12.pdf."},{"key":"127356","doi-asserted-by":"crossref","unstructured":"Potteg\u00e5rd A, Hallas J, Olesen M, Svendsen MT, Habel LA, Friedman GD, et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017; 282: 322\u2013331.","DOI":"10.1111\/joim.12629"},{"key":"127357","unstructured":"Defined Daily Dose (DDD). [Accessed: 2024 April 19]. Available from: https:\/\/www.who.int\/toolkits\/atc-ddd-toolkit\/about-ddd."},{"key":"127358","doi-asserted-by":"crossref","unstructured":"Ruiter R, Visser LE, Eijgelsheim M, Rodenburg EM, Hofman A, Coebergh JW, et al. High-ceiling diuretics are associated with an increased risk of basal cell carcinoma in a population-based follow-up study. Eur J Cancer 2010; 46: 2467\u20132472.","DOI":"10.1016\/j.ejca.2010.04.024"},{"key":"127359","doi-asserted-by":"crossref","unstructured":"Siiskonen SJ, Koomen ER, Visser LE, Herings RM, Guchelaar HJ, Stricker BH, et al. Exposure to phototoxic NSAIDs and quinolones is associated with an increased risk of melanoma. Eur J Clin Pharmacol 2013; 69: 1437\u20131444.","DOI":"10.1007\/s00228-013-1476-x"},{"key":"127360","doi-asserted-by":"crossref","unstructured":"Hou A, Li Y, Shadyab AH, Han J, Eaton CB, Qureshi A, et al. Photosensitizing antihypertensive medication and risk of skin cancer among postmenopausal women. J Dtsch Dermatol Ges 2024; 22: 186\u2013194.","DOI":"10.1111\/ddg.15281"},{"key":"127361","doi-asserted-by":"crossref","unstructured":"Br\u00f8ndum-Jacobsen P, Nordestgaard BG, Nielsen SF, Benn M. Skin cancer as a marker of sun exposure associates with myocardial infarction, hip fracture and death from any cause. Int J Epidemiol 2013; 42: 1486\u20131496.","DOI":"10.1093\/ije\/dyt168"},{"key":"127362","doi-asserted-by":"crossref","unstructured":"Birkeland SA, L\u00f8kkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000; 355: 1886\u20131887.","DOI":"10.1016\/S0140-6736(00)02298-4"},{"key":"127363","doi-asserted-by":"crossref","unstructured":"Tseng HW, Shiue YL, Tsai KW, Huang WC, Tang PL, Lam HC. Risk of skin cancer in patients with diabetes mellitus: a nationwide retrospective cohort study in Taiwan. Medicine (Baltimore) 2016; 95: e4070.","DOI":"10.1097\/MD.0000000000004070"},{"key":"127364","doi-asserted-by":"crossref","unstructured":"Corazza M, Ferretti S, Scuderi V, Borghi A. Socioeconomic status and skin cancer incidence: a population-based, cohort study in the province of Ferrara, northern Italy. Clin Exp Dermatol 2021; 46: 1285\u20131289.","DOI":"10.1111\/ced.14599"},{"key":"127365","doi-asserted-by":"crossref","unstructured":"Kiiski V, de Vries E, Flohil SC, Bijl MJ, Hofman A, Stricker BH, et al. Risk factors for single and multiple basal cell carcinomas. Arch Dermatol 2010; 146: 848\u2013855.","DOI":"10.1001\/archdermatol.2010.155"},{"key":"127366","unstructured":"R Core Development Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2021."},{"key":"#cr-split#-127367.1","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some drugs and herbal products. 2015"},{"key":"#cr-split#-127367.2","unstructured":"108. IARC Monogr Eval Carcinog Risks Hum 2016: 108: 7-419."},{"key":"127368","unstructured":"FDA approves label changes to hydrochlorothiazide to describe small risk of non-melanoma skin cancer . 2020. [Accessed: 2023 November 21]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-label-changes-hydrochlorothiazide-describe-small-risk-non-melanoma-skin-cancer."},{"key":"127369","doi-asserted-by":"crossref","unstructured":"Rouette J, Yin H, Potteg\u00e5rd A, Nirantharakumar K, Azoulay L. Use of hydrochlorothiazide and risk of melanoma and nonmelanoma skin cancer. Drug Saf 2021; 44: 245\u2013254.","DOI":"10.1007\/s40264-020-01015-1"},{"key":"127370","doi-asserted-by":"crossref","unstructured":"Steckelings UM, Artuc M, Wollschl\u00e4ger T, Wiehstutz S, Henz BM. Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol 2001; 81: 321\u2013325.","DOI":"10.1080\/000155501317140007"},{"key":"127371","doi-asserted-by":"crossref","unstructured":"Alrashidi A, Rhodes LE, Sharif JCH, Kreeshan FC, Farrar MD, Ahad T. Systemic drug photosensitivity: culprits, impact and investigation in 122 patients. Photodermatol Photoimmunol Photomed 2020; 36: 441\u2013451.","DOI":"10.1111\/phpp.12583"},{"key":"127372","doi-asserted-by":"crossref","unstructured":"G\u00f6tzinger F, Reichrath J, Millenaar D, Lauder L, Meyer MR, B\u00f6hm M, et al. Photoinduced skin reactions of cardiovascular drugs: a systematic review. Eur Heart J Cardiovasc Pharmacother 2022; 8: 420\u2013430.","DOI":"10.1093\/ehjcvp\/pvac017"},{"key":"127373","doi-asserted-by":"crossref","unstructured":"Koronellos N, Yapijakis C, Katoulis A, Avgoustidis D, Vylliotis A, Papakosta V, et al. Association study indicates combined effect of interleukin-10 and angiotensin-converting enzyme in basal cell carcinoma development. Arch Dermatol Res 2021; 313: 373\u2013380.","DOI":"10.1007\/s00403-020-02113-x"},{"key":"127374","doi-asserted-by":"crossref","unstructured":"Yapijakis C, Koronellos N, Spyridonidou S, Vylliotis A, Avgoustidis D, Goutas N, et al. Association of angiotensin-converting enzyme gene insertion\/deletion polymorphism with decreased risk for basal cell carcinoma. Arch Dermatol Res 2013; 305: 333\u2013339.","DOI":"10.1007\/s00403-012-1312-7"},{"key":"127375","doi-asserted-by":"crossref","unstructured":"Batalla-Covello J, Ali S, Xie T, Amit M. \u03b2-Adrenergic signaling in skin cancer. FASEB Bioadv 2022; 4: 225\u2013234.","DOI":"10.1096\/fba.2021-00097"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/42749\/51530","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/42749\/51530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:06:59Z","timestamp":1758618419000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/42749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":39,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.42749","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,23]]}}}